Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain:results of phase 2 of theVICOXX study

References

• Arboleya LR, de la Figuera S, García MS, Aragón B, and the VICOXX Study Group. Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs. Curr Med Res Opin 2003;19(4):278–287
   PubMed Web of Science ®Google Scholar
• Dolce JJ, Crisp C, Manzella B, Richards JM, Hardin M, Bailey WC. Medication adherence patterns in chronic obstructive pulmonary disease. Chest 1991;99:837–41
   PubMed Web of Science ®Google Scholar
• Watson DJ, Harper SE, Zhao P-L, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase inhibitor rofecoxib compared with non-selective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160: 2998–3003
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Lanas A. Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects [Spanish]. Med Clin (Barc) 2000;114(Suppl 3):46–53
   PubMedGoogle Scholar
• Schnitzer TJ. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 2001;23:1984–98
   PubMed Web of Science ®Google Scholar
• Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Schneidman R. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organization. Pharmacoeconomics 1997;12:76–88
   PubMed Web of Science ®Google Scholar
• Moore RA. The hidden costs of arthritis treatment and the cost of new therapy – the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002;41(Suppl 1):7–15
   PubMed Web of Science ®Google Scholar
• Fendrick AM. Developing an economic rationale for the use of selective COX-2 inhibitors or patients at risk for NSAID gastropathy. Cleve Clin Med J 2002;69(Suppl 1):S159–S164
   Google Scholar
• Laine L, Bombardier C, Ramey DR, Watson DJ, Pellisier JM, Reicib A. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study. Ann Rheum Dis 2001;60(Suppl 1):278 (abstract)
   PubMed Web of Science ®Google Scholar
• Russo P, Capone A, Attanasio E, et al. Pharmacoutilisation and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice. Rheumatology 2003; March 31 (epub ahead of print)
   Google Scholar
• Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001;23:1323–38
   PubMed Web of Science ®Google Scholar
• Ehrich EE, Schnitzer TJ, McIlwain H, et al. for the Rofecoxib Osteoarthritis Pilot Study Group. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week, double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26: 2438–47
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized clinical trial in patients with osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:978–87
   PubMed Web of Science ®Google Scholar
• Day R, Morrison B, Luza-Castenada O, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160: 1781–7
   PubMed Web of Science ®Google Scholar
• Truitt KE, Sperling RS, Ettinger Jr WH, et al. for the Phase III Rofecoxib Geriatric Study Group. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging Clin Exp Res 2001;13:112–21
   Web of Science ®Google Scholar
• Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002;287:64–71
   PubMed Web of Science ®Google Scholar
• Steinfeld S, Poriau S. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA survey. Cur Med Res Opin 2001;17:1–7
   PubMed Web of Science ®Google Scholar
• Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002;18:229–36
   PubMed Web of Science ®Google Scholar